

CORRECTION

Open Access



Correction: Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Masanobu Ueno¹, Ippei Miyagawa^{1,2,3}, Yusuke Miyazaki¹, Kentaro Hanami¹, Shunsuke Fukuyo¹, Satoshi Kubo¹, Shingo Nakayamada¹ and Yoshiya Tanaka^{1*}

Correction: *Arthritis Res Ther* 24, 240 (2022)
<https://doi.org/10.1186/s13075-022-02934-3>

Following publication of the original article [1], the authors reported an error in Additional file 1: Figure S1, Panel (C), subpanel c) a description regarding the gating strategy for the activated Th17 cells.

The data currently reads:

Activated Th17 cells: CD3⁺, CD4⁺, CXCR3⁺, CCR6⁺, CD38⁺, HLA-DR⁺

The data should read:

Activated Th17 cells: CD3⁺, CD4⁺, CXCR3⁻, CCR6⁺, CD38⁺, HLA-DR⁺

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13075-023-03005-x>.

Additional file 1: Figure S1. Flow cytometry gating strategy. The proportion of A. CD4⁺ T cells subsets to CD3⁺ and CD4⁺ T cells (%), B. CD8⁺ T cells subsets to CD3⁺ and CD8⁺ T cells (%), C. a)-e) Activated CD4⁺ T cells to CD3⁺ and CD4⁺ T cells (%), f) Activated CD8⁺ T cells to CD3⁺ and CD8⁺ T cells (%), D. B cells subsets to CD3⁻ and CD19⁺ B cells (%), E. Classical and non-classical monocytes to CD3⁻, CD19⁻, CD20⁻ and CD14⁺ cells (%), F. Myeloid and Plasmacytoid DCs to CD3⁻, CD19⁻, CD20⁻ CD14⁻ and human leukocyte antigen-DR⁺ cells (%), G. CD16⁺ and CD16⁻ NK cells to CD3⁻, CD19⁻, CD20⁻ CD14⁻ and CD56⁺ cells (%).

Published online: 14 February 2023

The original article can be found online at <https://doi.org/10.1186/s13075-022-02934-3>.

*Correspondence:

Yoshiya Tanaka
tanaka@med.uoeh-u.ac.jp

¹The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Kitakyushu 807-8555, Japan

²Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nurnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany

³Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nurnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany

Reference

1. Ueno M, Miyagawa I, Miyazaki Y, et al. Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes. *Arthritis Res Ther*. 2022;24:240. <https://doi.org/10.1186/s13075-022-02934-3>.



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.